These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30195018)

  • 1. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
    Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
    Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway.
    Xu X; Rajamanicham V; Xu S; Liu Z; Yan T; Liang G; Guo G; Zhou H; Wang Y
    Biomed Pharmacother; 2019 Jul; 115():108922. PubMed ID: 31048190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
    Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
    Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schisandrin B displays a protective role against primary pulmonary hypertension by targeting transforming growth factor β1.
    Wu J; Jia J; Liu L; Yang F; Fan Y; Zhang S; Yan D; Bu R; Li G; Gao Y; Chen Y
    J Am Soc Hypertens; 2017 Mar; 11(3):148-157.e1. PubMed ID: 28117274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.
    Yang X; Wang S; Mu Y; Zheng Y
    Oncol Rep; 2016 Oct; 36(4):1799-806. PubMed ID: 27499090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.
    Liu Z; Zhang B; Liu K; Ding Z; Hu X
    PLoS One; 2012; 7(7):e40480. PubMed ID: 22848381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schisandrin B inhibits TGF-β1-induced epithelial-mesenchymal transition in human A549 cells through epigenetic silencing of ZEB1.
    Zhuang W; Li Z; Dong X; Zhao N; Liu Y; Wang C; Chen J
    Exp Lung Res; 2019; 45(5-6):157-166. PubMed ID: 31268360
    [No Abstract]   [Full Text] [Related]  

  • 12. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of schisandrin B against cyclosporine A-induced nephrotoxicity in vitro and in vivo.
    Zhu S; Wang Y; Chen M; Jin J; Qiu Y; Huang M; Huang Z
    Am J Chin Med; 2012; 40(3):551-66. PubMed ID: 22745070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
    Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
    Chun J; Li RJ; Cheng MS; Kim YS
    Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
    Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
    Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
    Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.